Di Ma

5PUBLICATIONS
11CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 02, 2022
Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA.

Yan Li, Ziyi Xu, Shouzheng Wang

|Aug 14, 2019
Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: A retrospective, real-world study.

Guangjian Yang, Di Ma, Haiyan Xu

|May 17, 2019
Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations.

Shouzheng Wang, Puyuan Xing, Ke Yang

|Apr 18, 2019
Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib.

Di Ma, Yan Zhang, Puyuan Xing

|Mar 29, 2019
Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance.

Haiyan Xu, Guangjian Yang, Lu Yang

Pageof 1

Frequent Collaborators

3 joint publications

Junling Li

2 joint publications

Lu Yang

2 joint publications

Yuxin Mu

1 joint publications

Haiyan Xu